I think that where the technology is really disrupting is on the fact that you can scale
it up, which is not the case of all the cell culture systems that I have seen.
But it's something where you can really scale up, but what is really important is the fact
that you can conserve a certain quality of the cells.
And when we are talking about quality, actually in cell therapy, process is product.
Meaning that the quality of the cells is the key element of your therapy.
So this is where, I think, TreeFrog is making a big difference, where the competitive advantage is.
We are moving from 2D, 2D cells, taking a lot of labour, a lot of people working, into
a 3D environment where the cells can expand, with less money, with a better quality, meaning
that tomorrow everyone can have a benefit of that.
If I have to make a comparison, let's make it with the CHO cells.
CHO cells were introduced in the industry 30 years ago, and at that time, antibodies
that are today used in most of the therapies, where produced by hybridomas, where the scale-up
was quite limited actually, the production level was quite limited.
And then someone created the CHO cells - the Chinese Hamster Ovary cells - that were modified
to express antibodies.
Today, it is what we call a dominant design.
It is the most used cells in the therapies, and makes the scale-up efficient and makes
also these therapies affordable for people.
And I think that we are exactly following the same path for the cell therapies.
I am pretty sure that in the next 30 years, it will be the main way of producing cells
for cell therapy.